← Back to Screener
LENZ Therapeutics, Inc. Common Stock (LENZ)
Price$10.13
Favorite Metrics
Price vs S&P 500 (26W)-82.50%
Price vs S&P 500 (4W)-12.36%
Market Capitalization$319.19M
All Metrics
Book Value / Share (Quarterly)$9.07
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.95
Price vs S&P 500 (YTD)-40.51%
EPS (TTM)$-2.80
10-Day Avg Trading Volume0.65M
EPS Excl Extra (TTM)$-2.80
EPS (Annual)$-2.85
ROI (Annual)-28.88%
Gross Margin (Annual)97.81%
Cash / Share (Quarterly)$9.33
ROA (Last FY)-26.85%
EBITD / Share (TTM)$-3.16
ROE (5Y Avg)-34.74%
Cash Flow / Share (Annual)$-2.23
P/B Ratio1.12x
P/B Ratio (Quarterly)1.76x
Net Income / Employee (Annual)$-2
Net Interest Coverage (TTM)-1708.25x
ROA (TTM)-27.09%
EPS Incl Extra (Annual)$-2.85
Current Ratio (Annual)14.23x
Quick Ratio (Quarterly)13.81x
3-Month Avg Trading Volume1.08M
52-Week Price Return-55.85%
P/S Ratio (Annual)16.72x
Asset Turnover (Annual)0.06x
52-Week High$50.40
EPS Excl Extra (Annual)$-2.85
CapEx CAGR (5Y)-11.81%
26-Week Price Return-73.76%
Quick Ratio (Annual)13.81x
13-Week Price Return-45.24%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.23x
Enterprise Value$294.009
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-427.62%
Cash / Share (Annual)$9.33
3-Month Return Std Dev79.38%
Net Income / Employee (TTM)$-2
ROE (Last FY)-28.88%
EPS Basic Excl Extra (Annual)$-2.85
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.80
ROI (TTM)-28.75%
Revenue / Share (Annual)$0.66
Price vs S&P 500 (52W)-90.95%
Year-to-Date Return-36.38%
5-Day Price Return5.71%
EPS Normalized (Annual)$-2.85
ROA (5Y Avg)-33.02%
Net Profit Margin (Annual)-430.25%
Month-to-Date Return11.26%
EBITD / Share (Annual)$-3.16
Operating Margin (Annual)-477.46%
ROI (5Y Avg)-34.74%
EPS Basic Excl Extra (TTM)$-2.80
P/B Ratio (Annual)1.76x
Book Value / Share (Annual)$9.07
Price vs S&P 500 (13W)-48.10%
Beta2.16x
ROE (TTM)-28.75%
52-Week Low$8.25
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.38
4.38
4.38
4.38
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LENZLENZ Therapeutics, Inc. Common Stock | — | — | — | — | $10.13 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
LENZ Therapeutics is a late-stage biopharmaceutical company developing ophthalmic treatments for presbyopia, the age-related loss of near vision affecting the majority of people over 45. The company is advancing therapies to address this widespread condition in a large and growing market.